Best Immunotherapy doctors: TOP 21 doctors

Professor Zafer Gülbaş — hematologist-oncologist, founder and director of the Bone Marrow Transplant Center at Anadolu Medical Center, which is among the largest in Europe.

Why patients choose and trust Dr. Gülbaş:

• Built the Anadolu Bone Marrow Transplant Center from the ground up; the center has performed 3 000+ transplants (since 2010).
• 81% success rate for autologous transplants — a high figure according to the center’s data.
• International training and practice at leading institutions — Hadassah (Israel), Fred Hutch and MD Anderson (USA), Princess Margaret (Canada).
• 260+ scientific publications and 5 000+ citations — underscoring the professor’s significant contribution to transplantation.
• Anadolu Medical Center is an official partner of Johns Hopkins Medicine International, ensuring access to international protocols, multidisciplinary boards, and quality oversight.
• Manages the most complex cases: leukemias, lymphomas, aplastic anemia, and coagulopathies (clotting disorders).

Author of 40+ peer-reviewed publications in tumor biology/immunology and systemic therapy (immunotherapy and targeted therapy); member of the Turkish Medical Oncology Association and the European Head & Neck Society.

Why patients choose Dr. Bülent Karagöz:

• Treatment based on U.S. protocols through Anadolu Medical Center’s strategic collaboration with a leading U.S. institution — Johns Hopkins Medicine.
• 40+ scientific publications in tumor biology/immunology and systemic therapy (immunotherapy and targeted therapy).
• Former department head (GATA) and professor/department chair (Okan University, Turkey) — leadership and clinical experience at major centers.
• Treats solid tumors (e.g., breast, lung, colorectal), applying modern regimens guided by tumor biology.
• Anadolu Medical Center holds ESMO designation and JCI accreditation — meaning the doctor treats according to international protocols, within a multidisciplinary team, with strict safety oversight.

She has been working as an internal medicine specialist and medical oncology specialist at Anadolu Medical Center since 2021.
 

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

Dr. Pastrana is a board-certified surgical oncologist with expertise in immunotherapy at Galenia Hospital.

• Certified by Conacem – Mexico's leading medical accreditation body
• Active member of SMEO (Mexican Society of Oncology)
• University professor at Universidad Anahuac since 2020
• Title holder from Universidad Autónoma de México

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Sinan Karaaslan — Medical Oncologist at Anadolu Medical Center (since 2014). He treats breast, colorectal, and genitourinary cancers; in medical oncology since 2003. Member of the Turkish Medical Association, the Turkish Society of Medical Oncology, and the Turkish Lung Cancer Society.

Why patients choose and trust Dr. Karaaslan:

• Manages complex cases of breast, colorectal, and genitourinary cancers — applies modern systemic therapy tailored to the tumor type and stage.
• Member of the Turkish Medical Association, the Turkish Society of Medical Oncology, and the Turkish Lung Cancer Society.
• Author of numerous peer-reviewed articles and patient education materials on chemo- and immunotherapy.
• Practices at a center with ESMO Designated Centre status and JCI accreditation, within a strategic collaboration with Johns Hopkins Medicine International — one of the leading U.S. medical institutions. For patients, this means care aligned with U.S. protocols and the use of advanced equipment.

Prof. Şeref Kömürcü is an ECFMG and ESMO-certified medical and breast oncologist with over 20 years of experience. He specializes in solid cancer, breast cancer, colorectal and lung cancer treatment and has held teaching and scientific positions throughout his career. He is a member of several professional organizations.

Specialist Dr. Rahib Hasanov incorporates modern immunotherapy and targeted therapies into personalized oncology treatments, with international experience from Houston Methodist Hospital.

• Completed Medical Oncology fellowship at Marmara University Faculty of Medicine
• Attended numerous national and international congresses on oncology advancements
• Specializes in lung cancer, including immunotherapy treatments
• Treats patients from across Europe, the US, and Middle Eastern countries

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Osama Abdel Mohimen Mohamed is Head of the Hematology Unit at Shefaa Al Orman Oncology Hospitals. He is also a consultant in medical oncology and hematology at Shefa El Orman Hospital (NGO), Luxor (2019–present).

He diagnoses and treats acute and chronic leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. He also manages complications of solid tumors.

Background: He served at the National Cancer Institute, Cairo University, as a medical oncology resident, then demonstrator and assistant lecturer (2008–2022). Earlier, he was a house officer (2006–2007). He also held specialist roles at Al Salam International, Al Molalmen, and BAHEYA Oncology Center (NGO).

Memberships: ESMO (2008–present). American Society of Bone Marrow Transplantation (2009). ASH (2010).